99 Wall Street, Suite 232, New York, NY 10005

Need Help? Call : (800) 991-3756

Class Action Cases

A class action has been filed on behalf of CORV Investors. Click "Join this Class Action" above.

Attorneys

Correvio Pharma Corp.

Join Class Action »

Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Correvio Pharma Corp. (NASDAQ: CORV) from October 23, 2018 through December 5, 2019 (the “Class Period”). The lawsuit seeks to recover damages for Correvio Pharma Corp. investors under the federal securities laws.

If you bought Correvio Pharma Corp. securities between October 23, 2018 through December 5, 2019, and would like to join the action, please click “Join This Class Action,” above.

Press Release

SHAREHOLDER ALERT: Zhang Investor Law Announces a Securities Class Action Lawsuit Against Correvio Pharma Corp. – CORV

New York, N.Y., December 13, 2019. Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Correvio Pharma Corp. (NASDAQ: CORV) between October 23, 2018 and December 5, 2019, inclusive (the “Class Period”).

To join the CORV class action, go to http://zhanginvestorlaw.com/cases/correvio-pharma-corp/ call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU NEED NOT BE A LEAD PLAINTIFF TO SECURE A RECOVERY.

According to the lawsuit, throughout the Class Period (1) the data supporting the Resubmitted New Drug Application (“NDA”) for Brinavess did not minimize the significant health and safety issues observed in connection with the drug’s original NDA; (2) the foregoing substantially diminished the likelihood that the U.S. Food and Drug Administration would approve the Resubmitted NDA; and (3) as a result, Correvio’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 10, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/correvio-pharma-corp/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at info@zhanginvestorlaw.com.

Zhang Investor Law represents investors worldwide.